What isGHK-CuFDA Status, Evidence and Risks (2026)
Be first to know.Email the day GHK-Cu's FDA or HHS status changes.
Updates only. Doesn't reserve treatment. Unsubscribe anytime. Privacy
Split by route. Topical and other non-injectable GHK-Cu: back in Category 1 since May 14, 2026. Injectable GHK-Cu: off Category 2 since Apr 2026, review pending. Neither route is approved by FDA or on the 503A bulks list 1,2,3.
Part of The Sommar Peptide Guide. GHK-Cu is in copper peptide serums and in vials sold for injection. FDA treats those two routes differently. Education only.
What GHK-Cu is
GHK is a tripeptide, three amino acids: glycine, histidine and lysine. GHK-Cu is GHK bound to copper, also called copper tripeptide-1.
GHK occurs naturally in human plasma, saliva and urine, and its levels decline with age 4. It has been studied for wound healing and skin repair, mostly in cells and animals 4.
The split, by date
GHK-Cu has the most confusing status on FDA's lists 1,2,3.
| Date | What happened |
|---|---|
| Apr 2026 | Injectable GHK-Cu was one of 12 peptides FDA removed from Category 2 after nominations were withdrawn 8. |
| Apr 22, 2026 | FDA's nominated-substances list shows GHK-Cu taken off Category 1. |
| May 5, 2026 | The nominator clarified it had withdrawn only the injectable route. |
| May 14, 2026 | FDA put GHK-Cu back in Category 1 for non-injectable routes only. |
So today, two statuses:
- Topical and other non-injectable routes: Category 1.
- Injectable: off Category 2, not in Category 1, and due for review by FDA's Pharmacy Compounding Advisory Committee before the end of Feb 2027. No date is set 6.
One more moving part. On Oct 28, 2026, HHS filed an interim enforcement discretion policy covering six peptides: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV 9. GHK-Cu is not one of them, in any form, and keeps its prior status, as of Oct 29, 2026.
What Category 1 does and doesn't mean
Category 1 is a compounding category. It sorts substances that pharmacies have nominated for the 503A bulks list while FDA reviews them 1.
| Category 1 means | Category 1 does not mean |
|---|---|
| The substance was nominated with enough information for FDA to evaluate it 1. | FDA approved it. GHK-Cu is not approved by FDA for any use. |
| It may be eligible for the 503A bulks list 1. | It is on that list. It is not 1. |
| FDA "does not intend to take action" against a licensed 503A pharmacy compounding with it for a patient's prescription, if the guidance's conditions are met 1. | FDA found it safe or effective. Category 1 is an interim policy while the review runs. |
| It covers the non-injectable routes named, as of May 14, 2026 2. | It covers injections. Injectable GHK-Cu is not in Category 1. |
Category 1 also says nothing about serums on a store shelf. Those are sold as cosmetics. Under US law, cosmetic products and ingredients do not need FDA approval before sale, color additives aside 7. A product sold to treat a condition is regulated as a drug, even if it also changes appearance 7.
One name covers a cosmetic serum, a compounded topical made by a pharmacy and an injectable vial, each under different rules. Are Peptides Legal? covers how the categories work.
What the research shows
The evidence is mostly preclinical (cell and animal), plus cosmetic studies on skin. We found no human data for injected GHK-Cu, and no country that has approved it as a drug.
- Cells and animals. GHK-Cu affects collagen and other skin structural molecules, the enzymes that break them down, and the movement of immune and blood vessel cells to wounds. These effects come from lab and animal studies 4.
- Gene studies. A 2015 review reports GHK can turn up or down at least 4,000 human genes, based on gene-expression data, not treatment trials 4.
- Cosmetic studies on skin. The same review summarizes cosmetic studies reporting improvements in firmness, elasticity, fine lines and pigmentation 4. Both reviews cited here were written by the researcher who first isolated GHK, with a skin care company affiliation, and a 2018 paper by the same group says "the time has come for conducting actual clinical studies" on its anti-cancer claims 5.
- Hair. Claims for copper peptides and hair growth trace to work in mice 5. We found no human trial to cite.
Known risks and FDA's concerns
FDA's stated concerns for injectable GHK-Cu 3,8:
- Immune reactions. Peptides can clump (aggregate) or carry impurities that trigger the immune system. FDA flags this for injection.
- Limited human data. FDA's concern is the lack of safety information in people for the injectable route.
For topical GHK-Cu, we found no large published safety studies to cite. Its return to Category 1 is not a safety finding 1.
Why it's sold online anyway
Injectable GHK-Cu is easy to find in vials labeled "research use only" or "not for human consumption." That label is the seller saying the product is not made for people. It skips a prescriber and any quality check for human use. The topical Category 1 status does not extend to these vials. Prescription vs Research Peptides has more.
Other peptides on this shelf: Melanotan II, also awaiting review, and kisspeptin-10, the only peptide still on the pharmacy Category 2 list.
Asked a lot.
The sources.
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
- FDA. Bulk drug substances nominated for use in compounding under section 503A, Categories 1 to 3 (updated May 14, 2026). Read it
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. Read it
- Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. Read it
- Holland & Knight. Peptides at a Crossroads: What Wellness Providers Need to Know (Oct 16, 2026). Read it
- FDA. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated (content current as of Nov 18, 2025). Read it
- Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
Be first to know.
Get an email the day GHK-Cu's FDA or HHS status changes. Updates are for education only. Joining doesn't reserve treatment.
Email only. Please don't share health details here. Privacy Policy